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INTRODUCTION 
 
Type 2 diabetes is one of the most common chronic 
diseases in older populations, affecting ~ 20.0% of 
individuals with age >75 years [1, 2]. A considerable 
proportion of these older individuals have multiple 
comorbidities due in part to their longevity [3, 4]. Older 
individuals with diabetes have significantly increased 
risk of microvascular and macrovascular disease, 
cognitive dysfunction, functional impairment, 
depression, and vision and hearing impairment 
compared with younger adults [5, 6]. Further, the high 
prevalence of polypharmacy in elderly patients exposes 
them to a greater risk of complications and adverse 
reactions to any new pharmaceutical intervention [6]. 
However, frailty and multiple comorbidities have led to 
the exclusion of elderly patients from a majority of 
clinical trials of glycemic therapeutics until recently [6–
9]. The recent global guidelines for the treatment of 
elderly patients have emphasized on the need of a 
holistic and individualized approach to patient 
management and setting appropriate targets for this 
population [2, 6–10]. However, there is no evidence to 
date that setting these individualized targets is even 
feasible, let alone assessing whether they can be 
achieved or improve outcomes [5, 6, 9, 10]. 
 
The INdividualized Treatment targets for EldeRly 
patients with type 2 diabetes using Vildagliptin Add-on 
or Lone therapy (INTERVAL) study was the first, and 
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ABSTRACT 
 
We tested the feasibility of setting individualized glycemic goals and factors influencing targets set in a clinical 
trial in elderly patients with type 2 diabetes. 
A 24-week, randomized, double-blind, placebo-controlled study was conducted in 45 outpatient centers in 
seven European countries. 278 drug-naïve or inadequately controlled (mean HbA1c 7.9%) patients with type 2 
diabetes aged ≥70 years with HbA1c levels ≥7.0% and ≤10.0% were enrolled. Investigator-defined individualized 
HbA1c targets and the impact of baseline characteristics on individualized treatment targets was evaluated. 
The average individualized HbA1c target was set at 7.0%. HbA1c at baseline predicted a target setting such that 
higher the HbA1c, more aggressive was the target (P<0.001). Men were more likely to be set aggressive targets 
than women (P=0.026). Frailty status of patients showed a trend towards significance (P=0.068), whereas 
diabetes duration, age, or polypharmacy did not. There was heterogeneity between countries regarding how 
baseline factors were viewed.  
Despite training and guidance to individualize HbA1c goals, targets were still set in line with conventional 
values. A strong influence of country-specific guidelines on target setting was observed; confirming the 
importance of further education to implement new international guidelines in older adults. 
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to date the only, clinical study that pragmatically 
assessed the feasibility of setting and achieving 
investigator-defined individualized treatment targets in 
elderly patients with type 2 diabetes [11]. Despite the 
guidance to set individualized targets based on patients’ 
comorbidities and baseline characteristics and the 
training provided to facilitate this endeavor, the mean 
individualized HbA1c target set was 7.0%, identical to 
the contemporaneous conventional guidelines.  
 
Current guidelines advocate individualizing goals, yet 
our investigators, with a particular interest in diabetes in 
older adults and despite specific training in establishing 
these targets, deviated only marginally from 
conventional targets. To understand the factors that may 
hinder the application of global guidelines to 
individualize goals, we now review the targets set by 
these trained investigators, the determinants of those 
targets and the factors impacting HbA1c reduction. 
 
RESULTS 
 
The study enrolled 278 patients in total. Patients’ 
demographic characteristics have been presented in 
detail elsewhere [11]. In brief, 152 (54.7%) patients 
were female, 124 (44.6%) patients were aged ≥75 years 
and 26 (9.4%) patients reached the stringent criteria for 
frail (although physicians regarded more of their 
patients as frail according to general clinical 
judgement). The mean (standard deviation) age was 
74.8 (4.17) years (range, 70–97 years) and body mass 
index 29.8 (4.34) kg/m2. The mean (standard deviation; 
range) HbA1c was 7.9% (0.72; 6.6% to 10.3%), with 
173 (62.2%) patients with HbA1c levels of ≤8.0%, 
despite a mean (standard deviation; range) duration of 
diabetes of 11.4 years (7.47; 0.3 to 35.0 years). The 
patients were taking an average of six (range, 1–15) 
different medications, with a substantially higher tablet 
burden, before randomization to study drug or placebo. 
 
A summary of the individualized HbA1c targets set by 
the investigators by countries is provided in Figure 1. 
The mean overall HbA1c target reduction was −0.9% 
(range, −4.4% to −0.1%). In patients with HbA1c up to 
8.0%, the mean individualized target reduction was less 
stringent, −0.7% (range, −2.4% to −0.1%), whereas in 
patients with HbA1c >8.0% the mean individual target 
reduction was −1.2% (range, −4.4% to −0.2%). 
 
The impact of baseline characteristics on target setting, 
overall and by country, is summarized in Figure 2a. In 
the overall study, screening HbA1c was positively 
associated with the target reduction such that for every 
1% increase in the baseline HbA1c, the target reduction  
 
Figure 1. Summary of individualized HbA1c targets set by investigators (by country). 
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Figure 2. (A) Baseline factors affecting target setting (overall and by country). *For categorical covariates, the estimate is the 
difference between the adjusted means of comparison-reference in the corresponding category. For continuous covariates, the 
estimate is the change in adjusted means per unit. **Patients from Finland were identified by a single investigator. The figure 
estimates the difference between adjusted means for different factors potentially driving the individualized target setting and thus 
no reliable statistics for such a low sample size (n=2) could be generated. Hence, Finland has been removed. (B) Baseline HbA1c 
versus target reduction HbA1c. (C) Sex status versus target reduction HbA1c. (D) Baseline weight versus targeted individualized 
HbA1c by frailty status.  
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was increased by −0.5% (Pearson’s correlation −0.6353; 
P<0.001; Figure 2b). Men were set more aggressive 
targets than women (P=0.026; Figure 2c), whereas the 
frailty status only demonstrated a trend towards 
significance (P=0.068). In non-frail patients, the 
baseline weight was a predictor of a less aggressive 
glycemic target setting (P=0.012) such that more obese 
patients were set more aggressive targets, while in frail 
patients, a lower body weight did not additionally 
impact the glycemic target (P=0.725; Figure 2d). 
Interestingly and unexpectedly, neither age (P=0.510) 
nor the duration of diabetes (P=0.760) had an impact on 
the targets set. Hematological and biochemical 
parameters also did not seem to predict the target 
established. Physicians did not seem to consider the 
degree of polypharmacy when setting targets (P=0.301); 
the addition of the number of concomitant prescriptions 
and other medications to the analysis model did not 
significantly alter any of the associations. 
 
When exploring determinants at the country level, 
screening HbA1c was the only universal factor affecting 
target setting (P<0.001). Sex was a significant factor in 
Slovakia (P=0.025) and showed a trend in Germany 
(P=0.057), similar to the overall study. The frailty status 
was a significant factor only in Germany (P=0.002), 
while it also showed a trend in Belgium (P=0.085). Age 
was a significant factor only in Great Britain (P=0.025),  
whereas duration of diabetes was a significant factor 
only in Slovakia (P=0.018). 
 
As previously reported, the adjusted odds ratio of 
achieving the individualized target in the overall study 
population was 3.16 (P<0.001) with study drug, 
vildagliptin, compared to placebo [11]. This was on a 
background of 37 (27%) participants achieving their 
target on placebo alone. Great Britain had the highest 
odds ratio (59.22; 95% confidence interval 3.00 to 
1168.96; P=0.007) driven predominantly by the low 
percentage of patients in the placebo group achieving 
their individualized targets (7.7%). Belgium, on the 
other hand, with the highest percentage of patients 
achieving targets with placebo alone (58.8%), had the 
least relative benefit by introduction of medication 
(odds ratio 1.13; 95% confidence interval 0.28 to 4.63; 
P=0.862) (Figure 3).  
 
DISCUSSION 
 
Although global guidelines for the management of type 
2 diabetes advocate individualization of target setting, 
to date, the INTERVAL study is the first and only 
clinical study to explore the feasibility of setting such 
targets, let alone the evaluation of achieving these in a 
clinical setting. Despite extensive training and guidance 
to regard local guidelines as a secondary consideration, 
in our study, physicians maintained the traditional goal 
of 7.0% for this elderly and frail cohort. Further, this 
study is the first to explore the independent 
determinants of the targets that were set and, thereby, 
determine the specific areas of education that may be 
required to facilitate more appropriate target setting for 
elderly adults with type 2 diabetes. Guidelines 
published by the European Diabetes Working Party for 
Older People (aged ≥70 years) [9], the Consensus 
Development Conference on Diabetes and Older Adults 
 
 
Figure 3. Summary of individualized HbA1c target response (overall and by country). *Patients from Finland were 
identified by a single investigator. The figure estimates the difference between adjusted means for different factors potentially 
driving the individualized target setting and thus no reliable statistics for such a low sample size (n=2) could be generated. Hence, 
Finland has been removed.  
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(aged ≥65 years) convened by the American Diabetes 
Association [6], the Position Statement of the American 
Diabetes Association and the European Association for 
the Study of Diabetes [3] and, more recently, the 
International Diabetes Federation [2], all recommend an 
HbA1c target of 7.0% to 7.5% for elderly patients with 
type 2 diabetes without major comorbidities and 7.6% 
to 8.5% for frail, dependent patients with multiple 
comorbidities and high risk of hypoglycemia. These 
recommendations are based on opinions of the 
respective committees and experts rather than actual 
clinical evidence [12], indeed, the limited data used for 
formulating these recommendations were extrapolated 
from younger patients as most clinical trials exclude 
frail elderly patients with polypharmacy and multiple 
comorbidities [2, 6, 9]. Furthermore, these guidelines 
also suggest a patient-centered approach by providing 
the patient and caregiver structured education about the 
disease and treatment options and taking into account 
their individual medical, social, and cultural 
circumstances. Each patient should have the opportunity 
to make an informed decision regarding their treatment 
targets and therapeutic options including lifestyle 
modifications and pharmaceutical interventions [7, 8]. 
This is similar to the guidance and training provided to 
the investigators in the INTERVAL study, all of whom 
had special interest in diabetes in the elderly. Therefore, 
the conventional target of 7.0% that was set here was 
cause for concern and suggests that significant 
additional resources will be required to facilitate a 
change in clinical practice in a wider arena. We suggest 
that the introduction of guidelines alone may be 
insufficient to change attitudes and establish 
individualized care that these guidelines are hoping to 
achieve. 
 
The physicians in one or more centers in some countries 
seemed to set rigid, particularly aggressive and uniform 
HbA1c targets even in these elderly patients with type 2 
diabetes. The median and mean target reductions in 
these countries were similar for all patients suggesting 
that these aggressive targets were not a response to 
differing baseline characteristics such as comorbidities 
and duration of disease but a blanket adherence to more 
historic, aggressive HbA1c targets.  
 
Unexpectedly, there was a paradoxical association 
between sex of the participant and individualized target 
set, with more aggressive targets being set for men 
compared with women, despite a higher attributable risk 
of hyperglycemia to the adverse consequences of 
diabetes in women than men [13–16]. One likely 
explanation for this finding may be that elderly women 
with diabetes were potentially perceived to be more 
prone to falls and fractures [3, 17], and investigators 
potentially wished to avoid hypoglycemia by setting 
less stringent targets. Alternatively, this finding could 
also be attributed to the incorrect assumption that older 
men have a higher risk of cardiovascular disease and, 
therefore, require more aggressive treatment [18, 19]. 
Either way significant education is required here. 
 
The frailty status showed a tendency towards 
significance in the overall population, but that may be 
attributed in part to stringency of the modified Fried 
criteria that were used to define frailty in this study.  
The lack of association between age or duration of 
diabetes and targets set may represent the distinction 
that occurs in older adults compared with younger 
populations, where chronological age is discounted in 
preference of biological age. We had no way of 
capturing this subjective and, often, subconscious 
assessment by our investigators. However, given the 
overall aggressive targets that were set, this could 
represent the direct converse; physicians today 
disregard age when setting targets for fear of being 
accused of discriminating against people based on age 
[20]. This is a significant barrier to optimizing treatment 
for elderly adults. 
 
Multiple co-morbidities and polypharmacy are other 
important factors in the management of older adults. 
Drug-drug interactions, increased risk of side effects 
particularly in patients with renal impairment, decreased 
adherence, less clinical benefit from otherwise 
appropriate medicines, and an increased risk of falling 
in older patients are all important considerations [6]. 
The study population was representative of the real 
world elderly patients with type 2 diabetes with the 
majority having multiple comorbidities and an average 
of six and up to 15 co-prescriptions pre-randomization, 
many with multiple daily dosing, further translating into 
a higher volume of tablets per person. Unpredictably, 
the number of medications did not impact 
individualized target setting in this study. This may be 
due to the perceived safety profile of the active agent, 
vildagliptin; however, it was disappointing that the 
implied multiple co-morbidities that accompany 
polypharmacy were not a consideration.  
 
Nevertheless, choosing an optimal target is not always 
easy. Lack of consensus even among internationally 
acknowledged diabetes experts in weighing 
appropriateness of factors for setting glycemic targets 
for individual patients has led to exploration of 
usefulness of a survey-based algorithm for target setting 
[21]. The proposed algorithm suggests considering 
factors, such as life expectancy and risk of 
hypoglycemia, as main drivers of target setting while 
resource setting or disease duration per se are 
considered less important [21]. However, despite 
helpful tools, such as algorithms, assessment of 
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cognitive function or patient’s adherence to therapy 
remain subjective, confirming that individualized target 
setting is still an art. 
 
Findings from the Diabetes Prevention Program 
suggested that adults aged ≥60 years showed better 
efficacy from lifestyle interventions than younger 
patients with type 2 diabetes [22]. This could explain 
the results from the INTERVAL study in which all 
patients seemed to benefit from the opportunity to 
interact with their physicians while setting their 
individualized treatment targets as evidenced in 
particular by the high percentage of patients (27%) in 
the placebo arm who reached their individualized 
targets. However, the proportion of patients in the 
placebo group achieving their individualized targets 
varied remarkably across countries. This may be due to 
variation in the background education provided to older 
adults. Adequate advice regarding lifestyle, diet and 
exercise prior to their enrolment into the study would 
tend to attenuate the placebo effect. In other centers, 
where the perception may be that elderly adults may not 
benefit from such advice or a system does not support 
such education, enrolment into the study would tend to 
generate an exaggerated efficacy of the patient 
engagement. We do acknowledge the small sample size 
of patients from each country limits the application of 
these results as representative of the entire country; 
however, they do provide a unique glimpse of the 
challenges in the synchronization of global guidelines 
with local clinical practices. 
 
The INTERVAL study introduced a unique endpoint of 
individualized glycemic treatment targets to guide the 
“real-life” approach for treatment of elderly patients 
with type 2 diabetes, and reflected the unmet clinical 
need to understand the importance of individualized 
target setting, particularly in a more fragile population. 
No studies on individualized treatment targets or 
assessments of tolerability of any individualized 
treatments have been reported prior to this study. The 
INTERVAL study was exploratory, and further work 
will be required to better understand the consequences 
of such individualization of glycemic targets and the 
determinants of the glycemic targets set.  
 
In conclusion, INTERVAL was the first study to 
explore the feasibility of setting individualized targets 
when managing diabetes in the growing elderly 
population. In our population of trained and motivated 
investigators, individualized treatment targets were 
disappointingly aligned with conventional guideline 
targets. Therefore, we suggest significant investment in 
the implementation and adaptation of the ubiquitous 
global treatment guidelines to personalize medicine in 
any population will be required before we can truly 
offer individualized care. 
 
MATERIALS AND METHODS 
 
Study Design and Patient Population 
 
This was a 24-week, randomized, double-blind, 
placebo-controlled study conducted at 45 outpatient 
centers in seven European countries (Belgium, Bulgaria, 
Germany, Finland, Slovakia, Spain, and United 
Kingdom) between 22 December 2010 and 14 March 
2012. Drug-naïve or inadequately controlled patients 
with type 2 diabetes aged ≥70 years with HbA1c levels 
≥7.0% and ≤10.0% at the screening visit were eligible 
to participate in this study. The frailty status of patients 
was evaluated using a modified version of the criteria 
proposed by Fried and colleagues [23]. Patients were 
considered frail if they met any two of the following 
three criteria: unintentional weight loss, slow walking 
speed, and poor grip strength as measured by a 
dynamometer.  
 
Study investigators were trained in individualizing 
treatment targets based on their clinical judgement 
considering characteristics, such as age, frailty, 
comorbidities, and baseline HbA1c values. During the 
randomization visit, each patient agreed to an 
individualized 24-week HbA1c target with the 
investigator.  Patients were provided with information 
about the meaning of their individualized treatment 
targets, triggers and symptoms of hypoglycemia, and 
appropriate treatment for adverse events. However, no 
formal diabetes education program was engaged, and 
agreement was sought from participants to maintain 
their current diet and exercise habits for the duration of 
the study. Patients were randomized in a 1:1 ratio to 
receive either vildagliptin (according to the label) or 
placebo. Study analyses were performed on the full 
analysis set (FAS), comprising all randomized patients. 
Further details of the study population and design are 
described elsewhere [11].  
 
Study Assessments and Endpoints 
 
We have previously reported the co-primary endpoints 
of proportion of patients reaching their investigator-
defined HbA1c target and reduction in the HbA1c value 
from baseline to week 24. The a priori secondary 
analyses presented herein evaluated the individualized 
HbA1c targets set by the investigators and the impact of 
baseline characteristics on these targets. Further, the 
response from baseline of the co-primary study 
endpoint of meeting the individualized treatment targets 
was also explored. 
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Statistical Analysis 
 
Logistic regression and descriptive statistics were used 
to asses: (a) target reductions set by the investigators 
(overall and by country); (b) impact of baseline 
characteristics (age, frailty status, sex, screening 
HbA1c, duration of diabetes, and number of 
medications at baseline visit) on target setting (overall 
and by country); and (c) individualized HbA1c target 
response at endpoint (overall and by country). We also 
assessed the absolute change in HbA1c by country 
using a regression model with terms for treatment and 
centered baseline HbA1c. The odds ratio, defined as the 
odds of responding in one group divided by the odds of 
responding in the second group, was also presented. The 
last observation carried forward method was used to 
handle missing data because of early discontinuation or 
data censoring. Continuous data were used, wherever 
possible, to maximize power. 
 
Abbreviations 
 
FAS, full analysis set; HbA1c, glycated hemoglobin; 
INTERVAL, INdividualized Treatment targets for 
EldeRly patients with type 2 diabetes using Vildagliptin 
Add-on or Lone therapy   
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